Pharmesis International Ltd.
5 Kallang Sector
#03-02
Singapore 349279
Company registration no.: 200309641E

RESPONSE TO QUERY ON FIRST QUARTER RESULT FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2017 ("RESULTS ANNOUNCEMENT")

The Board of Directors of Pharmesis International Ltd. ("Company") wishes to provide the following information in response to an email query from Singapore Exchange Securities Trading Limited ("SGX-ST") on 31 May 2017.

SGX's Query

We refer to Pharmesis International Ltd. (the "Company") announcement on 15 May 2017 ("1Q2017").

1) In the Company's 1Q2017, we note that out of the net profit of RMB 179,000 for 1Q2017, profit attributable to non-controlling interest amounted to RMB 656,000 while loss attributable to equity holders of the Company amounted to (RMB 477,000).

   i) Please elaborate why the loss was attributable to equity holders of the Company and a profit attributable to non-controlling interest.

Company's response:

In the Company's 1Q 2017 results announcement, the profit attributable to non-controlling interest amounted to RMB 656,000 came from our 51% owned subsidiary, Sichuan Longlife Pharmaceutical Co., Ltd ("Longlife") which was profitable in 1Q 2017. The loss attributable to equity holders of the Company amounted to (RMB 477,000) was the consolidated loss of Pharmesis International Ltd and its subsidiaries in 1Q 2017.

BY ORDER OF THE BOARD
Jiang Yun
Executive Director and Chief Executive Officer
2 June 2017